Drug Trial Radar · NCT07387926
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Jul 5, 2026
Primary completion
Sep 19, 2033
Study completion May 30, 2036
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multi-center, open-label, single arm study of asciminib in participants aged ≥1 year to ≤30 years old with r/r Ph+ or ABL-class Ph-like ALL. This study will have 2 parts: Part 1 dose escalation and Part 2 dose expansion. Part 1 dose escalation will enroll participants aged ≥1 year to ≤30 years to determine the recommended phase 2 dose (RP2D) of asciminib when administered with low intensity chemotherapy. Part 2 dose expansion will enroll participants aged ≥1 year to ≤30 years to evaluate safety, tolerability, and efficacy of asciminib at the RP2D with the treatment regimen.
Conditions
- Acute Lymphoblastic Leukemia
- Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
- Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Interventions
Asciminib Adult formulationDrug
oral, administered daily (twice daily for participants with known T315I mutation); Cycles 1, 2, 3
Asciminib Pediatric formulationDrug
oral, administered daily (twice daily for participants with known T315I mutation); Cycles 1, 2, 3
DexamethasoneDrug
Fixed doses, oral (preferred) or intravenous (IV) twice daily; Cycle 1, Days 1 - 14; (Cycle 1 = 28 days)
VincristineDrug
Fixed doses, IV, weekly; Cycle 1
BlinatumomabDrug
Dosing based on bone marrow disease burden and weight. Continuous IV infusion; Cycles 2, 3
Methotrexate (intrathecal)Drug
Intrathecal
Cytarabine (intrathecal)Drug
Intrathecal
Hydrocortisone (intrathecal)Drug
Intrathecal
Prednisolone (intrathecal)Drug
Intrathecal
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 Dose Escalation: Incidence of Dose Limiting Toxicities (DLTs) occurring during cycle 1 (debulking induction)Time frame: During Cycle 1 (Cycle 1 = 28 days)
- Part 1 Dose Escalation: Incidence and severity of adverse events (AEs) during cycle 1 (debulking induction)Time frame: During Cycle 1 (Cycle = 28 days)
- Part 2 Dose Expansion: Percentage of complete response/remission (CR) evaluable participants who achieve CR treated at recommended phase 2 dose (RP2D) (debulking induction)Time frame: End of Cycle 1 (Cycle 1 = 28 days)
Locations
9 sites in 6 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Sydney, New South Wales, Australia · Recruiting
Novartis Investigative Site
Brisbane, Queensland, Australia · Recruiting
Novartis Investigative Site
Melbourne, Victoria, Australia · Recruiting
Novartis Investigative Site
Marseille, France · Recruiting
Novartis Investigative Site
Ramat Gan, Israel · Recruiting
Novartis Investigative Site
Utrecht, Netherlands · Recruiting
Novartis Investigative Site
Seoul, South Korea · Recruiting
Novartis Investigative Site
Seoul, South Korea · Recruiting
Novartis Investigative Site
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.